ALFA Finder| Revenue growth | FY26 up 37.1% YoY; Q4 up 134.9% YoY. |
|---|---|
| Margins | Record Q4 EBITDA margin 40.5%; FY26 margin 29.4%. |
| Order book | CMS contributed over two-thirds of Q4 revenue. |
| Demand visibility | Strong pipeline visibility; peptide projects ramping up. |
| Management confidence | High confidence in long-term visibility anchored by commercial molecules. |
Growth
Q4 revenue grew 134.9% YoY to ₹788.7cr; FY26 revenue up 37.1% to ₹2053.1cr; FY26 PAT rose to ₹363.1cr.
Outlook
Aspirational 18-20% CAGR; peptide facility operational by July 2026; ₹397.1cr capex spent in FY26.
Risks
Business lumpiness, raw material price volatility, geopolitical risks in Middle East, and potential moderation of ROCE.
Earnings Call filed with BSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹20,404.00
- Market cap
- ₹26,178 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 57.9×Sector 43.8×
- Promoter holding
- 32.26%-0.36% QoQ
- FII holding
- 21.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q2 income and EBITDA fell sharply YoY, and PAT dropped 47%. Management blames commercial lumpiness, says H1 was in line, and declined to quantify FY27 growth or give molecule-level detail.
Neuland Laboratories Investor Presentation: Key Takeaways
Q2FY27 income Rs457.2 Cr (-11.4% YoY), PAT Rs51.1 Cr (-47.0%), EBITDA margin 22.9% on operating deleverage. H1FY27 income Rs1107.2 Cr (+35.6%), PAT Rs198.5 Cr (+80.2%). Capex-led R&D and peptide build-out.
Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.
Neuland Laboratories Q2 FY27 Results: Net Profit ₹51.6 Cr, Down 46.7% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹449.7 Cr (-12.6% YoY) and net profit of ₹51.6 Cr (-46.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.6 Cr · -46.7% YoY
Neuland Laboratories Other Announcement
Neuland Laboratories notified loss of 100 share certificates by shareholder Madan Mohan Singh. The company requested issuance of an entitlement letter in lieu of the lost certificates.
Neuland Laboratories Board Meeting Date
Neuland Laboratories will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.